drugset / Trial / NCT07612137
Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To evaluate the safety and tolerability of IBI3005 combination therapy in participants with advanced solid tumors; to evaluate the antitumor activity of IBI3005 combination therapy in participants with advanced solid tumors.
Timeline
- Start
- 2026-06-01
- Primary completion
- 2027-06-30
- Completion
- 2028-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | — |
| Subject | Carboplatin | Small molecule | — | — |
| Subject | IBI3005 | Monoclonal antibody | — | — |
| Subject | Limertinib | Small molecule | — | — |
| Subject | Osimertinib | Small molecule | — | — |
| Subject | Sintilimab | Monoclonal antibody | — | — |